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Abstract
Background: Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality.
About 10% of North American women will be diagnosed with breast cancer during their lifetime and 20% of those will die
of the disease. Breast cancer is a heterogeneous disease and biomarkers able to correctly classify patients into prognostic
groups are needed to better tailor treatment options and improve outcomes. One powerful method used for biomarker
discovery is sample screening with mass spectrometry, as it allows direct comparison of protein expression between normal
and pathological states. The purpose of this study was to use a systematic and objective method to identify biomarkers with
possible prognostic value in breast cancer patients, particularly in identifying cases most likely to have lymph node
metastasis and to validate their prognostic ability using breast cancer tissue microarrays.
Methods and Findings: Differential proteomic analyses were employed to identify candidate biomarkers in primary breast
cancer patients. These analyses identified decorin (DCN) and endoplasmin (HSP90B1) which play important roles regulating
the tumour microenvironment and in pathways related to tumorigenesis. This study indicates that high expression of
Decorin is associated with lymph node metastasis (p,0.001), higher number of positive lymph nodes (p,0.0001) and worse
overall survival (p=0.01). High expression of HSP90B1 is associated with distant metastasis (p,0.0001) and decreased
overall survival (p,0.0001) these patients also appear to benefit significantly from hormonal treatment.
Conclusions: Using quantitative proteomic profiling of primary breast cancers, two new promising prognostic and
predictive markers were found to identify patients with worse survival. In addition HSP90B1 appears to identify a group of
patients with distant metastasis with otherwise good prognostic features.
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Introduction
Breast cancer affects more than 1.6 million women worldwide
and takes more than 400,000 lives every year [1]. Patients with
local disease have a significantly better 5 year overall survival (OS)
(98%) than patients with lymph node (LN) metastasis (83.6%) or
distant metastasis (23%). LN and distant metastases are therefore
strong predictors of poor prognosis [2][3]. Determination of LN
status involves identification and excision of the sentinel lymph
node(s) and subsequent histological examination which may
include assessment of multiple levels with or without immunohis-
tochemical (IHC) staining [4][5]. It is recognized that about 5% of
patients determined to be LN negative in fact have metastatic
disease in the LN at the time of diagnosis [6] [7]. The clinical
challenge is to correctly identify those patients that have or will
develop LN or distant metastasis and that therefore will behave
poorly, and use this information to offer supplemental treatment
after local therapy. A sensitive and specific biomarker able to
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30992accurately predict disease recurrence and LN or distant metastasis
is lacking and markers of disease progression continue to be
needed to improve patient classification. Biomarkers such as CA
15-3 and CEA are employed to monitor the progress of the disease
as an indirect measurement of tumour burden but with somewhat
limited success and are not currently widely used in clinical
practice [8][9].
Differential proteomics can be used to differentiate between two
physiologic states using tissue samples that represent underlying
biology and pathology. Isotopic labelling [10] and label-free mass
spectrometry (MS) [11] proteomics enable the quantification of
proteins and thus allow direct comparison of protein expression
between two sample sets [12][13].
When organisms are exposed to harsh conditions a number of
changes occur at the cellular level including changes in the
secondary and tertiary structure of proteins which can lead to
alterations in a protein’s solubility, transport or ability to carry out
its function or to perform it efficiently. Stressors that can alter
protein structure include low glucose, hypoxia and acidic
conditions, which are commonly seen in tumour microenviron-
ments. One of many responses that take place when cells face
stressful microenvironments is a rapid and transient increase in the
expression of heat shock genes. Heat shock proteins, Heat shock
protein 90 kDa beta (Grp94) member 1 (HSP90B1) being one of
them, facilitate cell survival by stabilizing and refolding denatured
proteins after stress [14]. HSP90B1 also helps cells escape
apoptosis and preserves the function of various proto-oncogenes
important for breast cancer growth [15]. HSP90 proteins have
several client proteins including mutated p53 and B-RAF, BCR-
ABL, v-Src, ErbB-2, AKT, RAF-1, CDK4, VEGF and PIK3
[16][17]. The HSP90 family is comprised of 17 genes. Six have
been recognized as functional in humans and these are divided
into two groups: HSP90A (alpha), which includes HSP90AA1,
HSP90AA2, HSP90N and HSP90AB1, and HSP90B (beta), to
which HSP90B1 and TRAP1 (a.k.a HSP90B2P) belong. HSP90B
is the major form of HSP90 involved in normal cellular functions,
such as maintenance of the cytoarchitecture, differentiation and
cytoprotection [18][19]. Although each subgroup has slightly
different characteristic functions, their functions do overlap and it
is accepted that cell proliferation and differentiation are regulated
by both HSP90A and HSP90B [20]. HSP90B1 has 2 known splice
variants HSP90B1-201 and -202; data is lacking as to any
functional difference between the two splice variants.
The purpose of this study was to use a systematic and objective
method to identify protein biomarkers with possible prognostic
value in breast cancer patients, particularly in discriminating cases
most likely to have LN metastasis. Differential proteomic analyses
were conducted on whole tissue protein extracts of cancerous and
normal tissue from breast cancer patients identifying two
candidate biomarkers. These were subsequently validated using
prognostic tissue microarrays (TMAs).
Materials and Methods
Mass spectrometry Study Populations
Following University Health Network (UHN) Research Ethics
Board approval, frozen tumour tissue samples from nineteen
breast cancer patients (estrogen receptor (ER) positive and HER2
receptor negative) were identified and collected from the UHN
BioBank. Normal samples from tissues adjacent to the tumour
were collected from thirteen of nineteen patients. Cancer tissues
were assigned to two groups based on axillary LN status and the
thirteen normal tissue samples were used as controls for protein
quantification.
Tissue Sample Processing and Preparation
Individual tissue samples were thawed and washed three times
with 1 ml of a phosphate-buffered saline (PBS) protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO) and homogenized. Equal
amounts of protein were pooled from homogenized normal tissue
samples to form a universal normal control sample. 100 mgo f
protein from each of the nineteen tumour tissue samples and the
universal control were trypsinized and labeled with an iTRAQ tag
as per manufacturer’s instructions (Applied Biosystems, Foster
City, CA).
Trypsin digested and labeled samples were randomly assigned
to six 4-plex iTRAQ sets for LC-MS/MS analysis, with each set
consisting of the universal control and three tumour samples
(either two LN-negative samples and one LN-positive sample or
vice versa).
Each set of four iTRAQ labeled samples was pooled prior to
fractionation by strong cation exchange (SCX) chromatography
using an Agilent 1100 HPLC system (Santa Clara, CA) coupled to
a 15 cm long, 2.1 mm internal diameter Thermo BioBasic SCX
column (ThermoFisher Scientific, Waltham, MA). Fractionation
resulted in 30 SCX fractions per iTRAQ set, each of which was
dried with a Thermo Savant SC110A speed vacuum (Holbrook,
NY) and resuspended in 30 mL of 0.1% formic acid.
Stable isotope dilution (SID) experiments were performed using
spike-ins of six isotope-enriched peptides in all tissue samples and
analysis by selected reaction monitoring mass spectrometry (SRM-
MS). Peptides were obtained from Biomatik Corporation (Canada)
for HSP90B1 (P14625), 40S ribosomal protein S25 (P62851),
hemoglobin subunit alpha (P69905) and alpha actin cardiac
muscle 1 (P68032), additional peptides were obtained from
Thermo Scientific (USA) for GTP binding nuclear protein RAN
(P62826) and 14-3-3 protein zeta/delta (P63104).
Quadrupole Time-of-flight Mass Spectrometry
SCX fractions 6 through 25 were analyzed by nano LC-MS/
MS. A Proxeon nano-HPLC system (Odense, Denmark) was
coupled to a QSTAR Elite Q-q-TOF mass spectrometer (AB
SCIEX, USA). An information dependant data acquisition
experiment was carried out with the following parameters: 250
or 500 millisecond TOF MS scan of m/z 400 to m/z 1500, MS/
MS triggered on ions greater than m/z 400 and less than m/z 1500
with charge state 2 to 4 that exceeded 50 counts, former precursors
excluded for 180 seconds, one survey scan and three MS/MS
scans per cycle, 50 mDa mass tolerance, automatic collision
energy and automatic MS/MS accumulation with a maximum
accumulation of 2 seconds and a fragment intensity multiplier of
2. The second quadrupole (Q2) was manually set up with
parameters optimal for sequencing and iTRAQ quantification.
Data acquisition was conducted using Analyst QS 2.0 software
(AB SCIEX, USA).
Analysis of iTRAQ Dataset
Protein identification and relative quantification analyses were
conducted on iTRAQ data using ProteinPilot 2.01 software (AB
SCIEX, USA) based on the Paragon algorithm [21], using the
following parameters: 4-plex iTRAQ, MMTS (Cys alkylation),
trypsin, post-translational modifications including multiple phos-
phorylations, glycosylation, and other post-translational modifica-
tions due to sample processing; 66% minimum identification
confidence score. Absolute fold-changes (AFC) were derived for
each protein in each of the iTRAQ sets for 3 comparisons: LN
negative vs LN positive; LN negative vs normal and LN positive vs
normal. Requirements for putative differential expression were:
LN negative vs LN positive AFC$1.5 (113 proteins); or AFC$1.5
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comparison (12 proteins).
Selected Reaction Monitoring Mass Spectrometry
Specific SRM peptide precursor/product ion transitions were
designed for each protein based upon iTRAQ results using
MIDAS (MRM-initiated detection and sequencing) workflow
designer software (AB SCIEX, USA). Proteins were multiplexed
in sets of 50 for each SRM analysis of a patient sample using an
Eksigent nano-LC coupled to a 4000 QTRAP hybrid linear ion
trap/triple quadrupole mass spectrometer (AB SCIEX, USA)
through a nanoflow electrospray ionization source equipped with a
15 mm ID emittor tip.
Analysis of SRM Dataset
SRM raw data were pre-processed using MultiQuant 1.0
software (AB SCIEX, USA) to identify and derive peak areas for
SRM transitions. A 2-point Gaussian smoothing procedure was
applied to all peaks. Mean peak areas for each transition was
compared between LN negative and LN positive groups using a
test assuming unequal variance at a two-tailed significance (alpha)
threshold of 0.10. Analyses were conducted using R software.
In-House Human Breast Cancer Tissue Microarrays and
Immunohistochemistry
Tissue microarrays (TMAs) were constructed at UHN from
samples obtained from primary breast cancer patients admitted to
Princess Margaret Hospital between January and December of
2006. For all TMAs, 4 mm formalin-fixed, paraffin embedded
(FFPE) sections were dewaxed in five changes of xylene and
brought down to water through graded alcohols. Tissue sections
were microwaved in Tris-EDTA Buffer (pH 9.0) for antigen
retrieval.
After blocking for 15 minutes, sections were incubated at room
temperature overnight with the appropriate primary antibodies
using previously optimized dilutions. Primary antibody incubation
was followed by incubation with a biotinylated secondary antibody
(Vector Laboratories, Burlingame, CA) for 30 minutes and
horseradish peroxidase-conjugated ultrastreptavidin labeling re-
agent (ID Labs Biotechnology Inc., London, ON) for 30 minutes.
Stained TMA slides were scanned using a high-resolution bright
field ScanScope XT scanner (Aperio Technologies, Vista, CA) at
the Advanced Optical Microscopy Facility (AOMF) in the Ontario
Cancer Institute (OCI). Evaluation of immunohistochemical
staining was conducted using image analysis with Aperio Image-
Scope Software Version 9.0 (Aperio Technologies).
Statistical analysis was conducted using SPSS (Version 17.0 for
Windows) software package (SPSS Inc., Chicago, IL).
Prognostic Tissue-Microarrays, Immunohistochemistry
and Scoring
Duplicate sets of Stage I and II prognostic human breast cancer
TMAs were obtained from the National Cancer Institute (NCI)
Cancer Diagnosis Program (Silver Spring, MD), consisting of a
total of 990 (590 Stage I and 400 Stage II) distinct invasive breast
cancer cases. Details for the TMAs set may be found at http://
cdp.nci.nih.gov/breast/prognostic_cs.html.
A summary of patients’ clinical and pathological characteristics
for the TMAs is provided in Table S1. Immunostaining was
performed according to standard protocols using one of the
following primary antibodies: Decorin (HPA003315 - Sigma-
Aldrich, St. Louis, MO) at a concentration of 1:400 overnight,
HSP90B1 (HPA003901 - Sigma-Aldrich, St. Louis, MO) at 1:4000
for 1 hour, Ki-67 (SP6, LabVision, Fremont, CA) at 1:1000 for
1 hour, ER (SP1, LabVision) at 1:200 for 1 hour, and HER2 (4B5,
Ventana, Tucson, AZ) at 1:50 for 1 hour. A summary of marker
characteristics for DCN and HSP90B1 is provided in Table S2.
Tissue microarray IHC staining was evaluated under light
microscopy and with software-based image analysis (Aperio
Technologies, Vista, CA,). Decorin staining intensity was assessed
in both normal stromal cells and cancer epithelial cells separately
under light microscopy, HSP90B1 staining was scored in the
invasive cancer only. The average staining intensity of DCN
(Decorin_Iavg) and HSP90B1 (HSP90B1_Iavg) was quantified
Figure 1. Scoring system used for DCN and HSP90B1
immunohistochemistry. A, Strong DCN positivity in stroma (3+)
and negative in carcinoma (0) (magnification 2006). B, Strong DCN
positivity in carcinoma (3+), weak stromal positivity (1+) (2006). C,
Moderate HSP90B1 positivity in carcinoma (1+) (2006). D, Strong
HSP90B1 positivity in carcinoma (3+) (2006). Decorin antibody (Sigma-
Aldrich, St. Louis, MO) used at a dilution of 1:400. HSP90B1 antibody
(Sigma-Aldrich, St. Louis, MO) used at a dilution of 1:4000.
doi:10.1371/journal.pone.0030992.g001
Figure 2. Venn diagram of Differentially expressed proteins.
Number of proteins differentially expressed for each comparison group
as well as overlapping proteins. Node-negative breast cancer tissue
(group A), node positive BC tissue (group B), and normal breast tissue
(group N).
doi:10.1371/journal.pone.0030992.g002
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independently by two pathologists (DTT and JM) using a four
point semi-quantitative scale for intensity: 3+ (very strong), 2+
(strong), 1+ (moderate/weak), and 0 (no staining) (Figure 1). In
case of disagreement cores were reviewed together and consensus
was reached. TMAs were scanned at 206 and the ImageScope
Positive Pixel Count algorithm version 9.1 used for software-based
analysis on the entire core. An average intensity of positive pixels is
calculated by the software generating a continuous variable of
intensity scores in which higher scores (pixel colour closer to white)
mean lower staining intensity.
Given the heterogeneity and relatively low DCN epithelial
staining, any strong even if focal, cancer cell staining was
considered high expression, while due to the more diffuse
moderate to strong HSP90B1 positivity in the majority of cores,
we required both diffuse and strong HSP90B1 positivity to
categorize it as high expression. For analytical purposes, 3+ and 2+
staining were considered high expression for both DCN and
HSP90B1; and 1+ and 0 staining were considered low expression.
Evaluation of ER and HER2 staining was performed using current
recommendations [22], [23]. HER2 cases that were considered
equivocal (2+) were omitted from the analysis since fluorescence in
situ hybridization staining for HER2 was not available. Breast
cancer molecular subtypes were defined by IHC expression of ER,
and Ki-67 as suggested by Cheang et al and Hugh et al: Luminal
A (ER-positive, HER2-negative and low Ki67), luminal B (ER-
positive, HER2-positive and/or high Ki67), HER2 (ER-negative
and HER2-positive) and basal-like (ER-negative and HER2-
negative) [24][25].
Statistical Analysis of TMA Datasets
The association between demographic and clinicopathological
variables and the dichotomized values for DCN staining in stroma
and malignant tissue as well as HSP90B1 staining in tumour
tissues was evaluated using the Chi-square test for categorical
factors. Decorin_Iavg and HSP90B1_Iavg variables had a normal
distribution. The association between patient clinicopathological
variables and the continuous marker parameters Decorin_Iavg
and HSP90B1_Iavg were assessed using a two-sided t test or
ANOVA, as appropriate. Kaplan-Meier survival curves were
constructed for disease-free survival (DFS) and OS and differences
between groups were determined using the log-rank test. The
prognostic value of the dichotomized and continuous marker
parameters was evaluated using univariate and multivariable Cox
proportional hazard models, adjusting for clinicopathological
variables. All statistical analyses were performed using SAS 9.2
(SAS Institute, Cary, NC). All reported p values are two-sided and
a value ,0.05 was considered statistically significant. This study
has been designed and reported following the ‘‘Reporting
recommendations for tumour marker prognostic studies (RE-
MARK)’’ guidelines [26].
Results
Quantitative proteomic profiling using iTRAQ-labelling iden-
tified 988 proteins of which a subset of 477 were determined to be
differentially expressed between LN positive and LN negative
cancer tissues or between cancer and normal tissues based on a
minimum absolute fold-change of 1.5 (Figure 2). The ProteinPilot
search results of the iTRAQ experiments at the protein level are
presented in Table S3. Differential expression was verified by
targeted quantification using label-free and SID SRM-MS [11] on
breast tumour tissue. Over 70% of the significant proteins
identified by iTRAQ-MS were detected by label-free SRM-MS,
and differential expression of 49 proteins was confirmed (18
p,0.05 and 31 0.05,p,0.10), of which 23 displayed increased
expression and, 26 displayed decreased expression in LN positive
tissues (Table S4). Box plots summarizing these results are shown
in (Data S1). Further, SID SRM-MS using peptides from
HSP90B1 (P14625), 40S ribosomal protein S25 (P62851),
hemoglobin subunit alpha (P69905), alpha actin cardiac muscle
Table 2. Antibodies used to validate putative biomarkers.
Antibody Name Laboratory
Lumican precursor (LUM) Sigma-Aldrich
Endoplasmin (HSP90B1) Sigma-Aldrich
Alpha-2-HS-glycoprotein precursor (AHSG) Sigma-Aldrich
60-kDa heat shock protein mitochondrial
precursor (HSPD1)
Sigma-Aldrich
Ubiquitin carboxyl-terminal hydrolase 34 (USP34) Sigma-Aldrich
Decorin precursor (DCN) Sigma-Aldrich
Ceruloplasmin precursor (CP) Sigma-Aldrich
Glucose-6-phosphate-1-dehydrogenase (G6PD) Sigma-Aldrich
Nonhistone chromosomal protein HMG-17
(HMGN2)
Lifespan Biosciences
haptoglobin precursor (HP) Lifespan Biosciences
List of commercially available antibodies purchased, including manufacturing
laboratory, used to validate putative biomarkers. Only antibodies designed for
use on formalin fixed paraffin embedded tissue were used.
doi:10.1371/journal.pone.0030992.t002
Table 1. Confirmation of peptide identity using SID SRM-MS.
Name Accession Peptide used for SID Confirmed
Endoplasmin precursor P14625 SILFVPTSAPR Yes
40S ribosomal protein S25 P62851 LITPAVVSER Yes
Hemoglobin subunit alpha P69905 LRVDPVNFK Yes
Actin, alpha cardiac muscle 1 P68032 SYELPDGQVITIGNER Yes
GTP-binding nuclear protein RAN P62826 AAQGEPQVQFK No
14-3-3 protein zeta/delta P63104 NLLSVAYK Yes
List of peptides for which SID SRM-MS was used to confirm their identification. UniProtKB accession number and amino acid sequence are shown.
SID: Stable isotope dilution.
SRM-MS: selected reaction monitoring mass spectrometry.
doi:10.1371/journal.pone.0030992.t001
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additional 14-3-3 protein zeta/delta (P63104) confirmed the
identification of all except RAN (Table 1).
Ten proteins with commercially available antibodies were
screened on one tissue microarray (TMA) of invasive ductal
carcinoma (Table 2). Five candidates (HSP90B1, HMGN2,
USP34, DCN and G6PD) showed a tentative association with
LN status. HSP90B1 and DCN were positively correlated and
USP34, G6PD and HMGN2 were negatively correlated with
axillary LN status.
Mean TMA protein expression levels of HSP90B1 and DCN
showed the strongest statistical association with presence of LN
metastasis being significantly higher in LN positive tumours
relative to LN negative tumours (HSP90B1 p=0.049; DCN
p,0.001). Subset analysis of ER-positive and HER2-negative
cases revealed a greater mean expression difference for both
HSP90B1 and DCN. The expressions of HSP90B1, USP34 and
HMGN2 were significantly negatively associated with tumour
grade (p,0.001).
High DCN and HSP90B1 Predict Metastasis and Worse OS
Following the MS results the expression levels of DCN and
HSP90B1 and their association with clinicopathological charac-
teristics were further assessed in breast cancer tissues from an
independent cohort compiled by the NCI and distributed as breast
cancer prognostic TMAs.
Cytoplasmic staining was seen for both DCN and HSP90B1. Of
the 990 cases 928 (94%), 967 (98%) and 930 (94%) were
interpretable for DCN staining in stroma, DCN staining in the
carcinoma and HSP90B1 staining in the carcinoma, respectively.
High expression of DCN in stroma, carcinoma and HSP90B1
staining in carcinoma was seen in 76%, 34% and 84% of cases,
respectively (see Table S2).
High DCN expression in stroma correlated with lower tumour
grade (p,0.0001), Ki67 level #10% (p=0.005) and ER positivity
(p=0.0002). These correlations were also found with lower levels
of software-based scoring Decorin_Iavg, (all p,0.001). No
correlation was found between intensity of DCN staining in
stroma and LN status.
High expression of DCN in the malignant epithelium was
correlated with LN positivity (p,0.001), higher number of positive
lymph nodes (p,0.0001) and HER2-positive status (p=0.004)
compared to patients with low expression. Subgroup analysis by
molecular type showed similar odds ratios (OR) for this correlation
in 3 out of the 4, subgroups: luminal A (OR: 2.34), luminal B (OR:
2.39) and HER2 (OR: 2.39), respectively.
Patients with high expression of HSP90B1 in malignant cells
were more likely to have distant metastasis compared to patients
Table 3. Univariate and multivariate analysis of predictors of overall survival.
Overall Survival
Univariate Multivariate (N=864)
Characteristic Unadjusted HR (95% CI) p Adjusted HR (95% CI) p
Age #50 1.00 ,0.0001 1.00 ,0.0001
.50 1.99 (1.54–2.57) 2.73 (2.04–3.66)
Tumour Size #2 cm 1.00 ,0.0001 1.00 ,0.0001
.2 cm 1.83 (1.50–2.24) 1.59 (1.26–2.01)
Tumour Grade I 1.00 0.002 1.00 0.007
II 1.32 (1.04–1.67) 1.29 (0.66–1.67)
III 1.58 (1.23–2.04) 1.75 (1.23–2.47)
LN Status Positive 1.00 ,0.0001 1.00 0.001
Negative 1.63 (1.33–2.00) 1.50 (1.18–1.90)
Ki 67 #10 1.00 0.4 1.00 0.17
.10 1.10 (0.88–1.39) 0.76 (0.51–1.13)
Molecular Subtype Luminal A 1.00 0.49 1.00 0.59
Luminal B 1.19 (0.89–1.60) 1.35 (0.86–2.12)
Her2 1.25 (0.81–1.91) 1.04 (0.64–1.69)
Basal 1.12 (0.84–1.50) 1.25 (0.82–1.90)
Decorin Stroma Low 1.00 0.06 0.01
High 1.28 (0.99–1.65) 1.55 (1.11–2.17)
Decorin Epithelium Low 1.00 0.01 1.00 0.05
High 1.29 (1.06–1.57) 1.25 (0.998–1.55)
Decorin_avg 1.00 (0.997–1.006) 0.59
Decorin_Iwavg 1.00 (0.995–1.01) 0.49
HSP90B1 Epithelium Low 1.00 ,0.0001 1.00 ,0.0001
High 2.12 (1.48–3.02) 2.16 (1.49–3.14)
HSP90B1_Iavg 1.00 (0.996–1.008) 0.46 1.00 (0.996–1.01) 0.39
Univariate and Multivariable Cox proportional hazards regression to determine predictors of overall survival. Note: Molecular subtype was used in
place of ER and HER2 status; Decorin Iwavg was used in place of Decorin Iavg.
doi:10.1371/journal.pone.0030992.t003
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also found with lower levels (i.e. higher staining intensity) of
software-based scoring HSP90B1_Iavg (p=0.03). Lower levels of
HSP90B1_Iavg were also associated with tumour size #2c m
(p,0.0001), lower grade (p=0.001), negative LN status
(p,0.0001), Ki67#10 (p=0.002) and ER positivity (p=0.002)).
Performance analysis revealed that high DCN expression in the
malignant tissue predicts LN metastasis with a sensitivity of 48%
and a specificity of 70.8%. High HSP90B1 expression in
malignant epithelial cells predicts distant metastasis with a
sensitivity of 97.1% and a specificity of 14.2%.
Univariate Cox proportional hazards regression analysis found
higher staining of the malignant epithelial tissue with DCN and
HSP90B1 to be predictors of decreased OS with a HR equal to
1.29 (p=0.01) and 2.12 (p,0.0001), respectively. Age, tumour
size, tumour grade and LN status were also associated with OS. All
of these variables retained significance on multivariate analysis
(Table 3). Continuous markers (Decorin_Iavg and HSP90B1_
Iavg) were not found to be predictors of OS or DFS (DFS data not
shown).
Kaplan-Meier analysis (median follow-up of 12.8 years, range:
1.1 to 23.5 years) showed that patients whose tumours express high
levels of DCN or HSP90B1 in the malignant epithelium have
significantly lower OS and DFS compared to patients with lower
expression of either marker (Figure 3). Combination group
analysis showed that patients with high expression of both markers
have the worse OS (p,0.0001) (Figure 4) and DFS (p,0.0001) of
all four groups.
Molecular subtype analysis indicated that high expression of
DCN in malignant epithelial cells is a predictor of decreased OS
(HR: 2.33 vs. low expression p=0.002) only in luminal B subtype
tumours (Figure 5) as is high expression of DCN in the benign
peri-lesional stroma (data not shown). High expression of
HSP90B1 in malignant epithelial cells is associated with lower
OS in all four groups: Luminal A (HR: 1.66 vs. low expression,
p=0.02), Luminal B (HR: 3.05 p=0.05), HER2 (HR: 6.25,
p=0.04) and basal subtype (HR: 3.19, p=0.02) (Figure 6). This
was also the case for DFS (data not shown).
Survival analysis based on hormone treatment group showed
that OS of patients in which malignant epithelial cells have high
expression of DCN or HSP90B1 benefited significantly from
hormone treatment (Figure 7), with a HR after hormone
treatment approaching that of patients with low expression of
both markers. Chemotherapy did not change OS in either group.
Figure 3. Overall and Disease-free survival based on high and low DCN and HSP90B1 staining. A, OS curve for DE. B, DFS curve for DE. C,
OS curve for HE. D, DFS curve for HE. DE: Decorin staining in malignant epithelial tissue. HE: HSP90B1 staining in malignant epithelial tissue. OS: Time
from diagnosis to death from any cause. DFS: Time from diagnosis to any recurrence or death from any cause.
doi:10.1371/journal.pone.0030992.g003
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The purpose of this study was to use a systematic and objective
method to identify possible biomarkers that could have prognostic
value in breast cancer patients, particularly in identifying cases
most likely to have LN metastasis. We performed differential
proteomic analyses of whole tissue protein extracts of cancerous
and normal tissue from breast cancer patients. The initial
discovery phase combined iTRAQ labelling with off-line two-
dimensional liquid chromatography tandem MS, for global,
unbiased protein profiling and quantification. Subsequently
label-free SRM-MS was used for targeted quantification of
differentially expressed proteins to verify differential expression
in individual tissue samples. In the end, parallel, isotope enriched
peptides for 6 significant proteins identified by iTRAQ-MS were
synthesized for SID SRM-MS analysis of individual tissue samples,
providing confirmation of identification for 5 proteins, including
HSP90B1. TMA analysis revealed that the expression levels of two
candidate markers were positively associated with LN metastasis:
DCN (p=0.001) and HSP90B1 (p=0.049) Finally, IHC analysis
using the NCI prognostic TMAs showed significant association of
high expression of DCN with LN metastasis, high expression of
HSP90B1 with distant metastasis and high expression of both
markers with decreased OS and DFS.
DCN and HSP90B1 play important roles in several biological
pathways related to tumorigenesis. Decorin is a key modulator of
the tumour microenvironment [27] through interactions with
EGFR and MAPK [28] pathways. Decorin also activates insulin-
like growth factor-I receptor [29], attenuates Erb2 signalling
[30], binds to TGF-Beta, activates Met and up-regulates p21
[31][32]. While in most studies DCN has been found to have an
antioncogenic role, others correlate DCN with increased
migration of human osteosarcoma cells [33] and high expression
in endothelial cells undergoing angiogenesis [34]. HSP90B1 is a
heat shock chaperone protein that stabilizes and refolds
denatured proteins after stress, facilitating cell survival during
conditions commonly seen in the tumour microenvironment
[33]. HSP90 proteins are involved in the glucocorticoid receptor
and the AKT signalling pathways [35][36], through these
interactions they increase glucose metabolism, cell proliferation,
transcription and cell migration and decreased apoptosis. HSP90
proteins have been found increased in metastatic melanoma
compared to the primary [37] and high HSP90 expression
predicts worse OS in patients with acute lymphocytic leukemia
[38] and breast cancer [39], and decreased DFS in gastrointes-
tinal stromal tumours [40]. Several phase II and III trials are
evaluating the anticancer activity of HSP90 inhibitors in several
types of cancer.
The MS findings suggested that high DCN and high HSP90B1
expression were associated with LN metastasis, with SRM-MS
based fold-change of 1.5 observed for DCN (p=0.06) and 2.0 for
HSP90B1 (p=0.007) in LN positive tissues. This association was
confirmed for DCN staining of epithelial cancer cells (p,0.001),
which was also associated with the number of positive LNs
(p,0.0001) and worse OS. It is interesting, albeit unexplained, to
find that in our study the negative prognostic value for survival in
patients with high DCN expression in malignant cells was clearly
significant in Luminal B cases (i.e. ER-positive, HER2-positive)
(HR: 2.33 p=0.002) while lacking any survival prognostic effect
on ER only or HER2 only positive tumours. Nevertheless, a
Figure 4. Overall survival curves using combinations of DE and HE expression levels. Univariate Cox regression used to determine HR;
logrank p-values reported; Bonferroni multiple testing adjustment for pairwise comparisons p=0.05/5=0.01. DE: Decorin staining in malignant
epithelial tissue. HE: HSP90B1 staining in malignant epithelial tissue. HR: Hazard ratio.
doi:10.1371/journal.pone.0030992.g004
Breast Cancer Decorin, HSP90B1 Metastases Survival
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30992marker of LN metastasis risk and worse OS risk exclusive to this
subgroup of patients could have clinical utility.
The expected association between high HSP90B1 expression
and LN metastasis was not seen, however a significant association
between high HSP90B1 expression and distant metastasis was
found (median follow-up 11.5 years, p,0.0001 for dichotomous
variable HSP90B1 epithelium and p=0.03 for continuous
variable HSP90B1_Iavg). Given that vascular endothelial growth
factor-A, a potent pro-angiogenic factor, is down-stream of the
EGFR pathway which is in turn increased by HSP90, it may be
that high levels of HSP90 could promote metastasis, and in fact an
association between high HSP90 expression and metastasis in
melanoma has been reported previously. However to the best of
our knowledge this association has not been described in breast
cancer. Even more interesting is the fact that high HSP90B1 levels
were also associated with parameters considered to confer good
prognosis to breast cancer patients (i.e. tumour size #2, lower
grade, negative LN status, ER positivity, Ki67#10 and lower
grade), although this association was found only with the software-
based score. Taken together these findings suggest that high
expression of HSP90B1 could potentially identify a subgroup of
patients that, based on currently used clinicopathologic variables,
are considered to have good prognosis and yet have shorter OS
and DFS. OS results found in combination group analysis suggest
that having high levels of HSP90B1 in malignant cells is worse
that having high levels of DCN. This was also supported in the
multivariate analysis as high HSP90B1 staining in malignant
epithelial cells had a higher HR than high DCN staining in the
same cells.
An important and novel finding is that in terms of OS, patients
with high expression of HSP90B1 in tumour cells appear to benefit
significantly from hormonal treatment (HR: 1.07 vs. 2.8 for no
hormone treatment group). This HR is similar to that of the group
with low expression of HSP90B1 in malignant epithelial cells. This
hormonal treatment effect cannot be explained by hormone
receptor status bias because OS was significantly better for patients
with low vs. high tumour expression of HSP90B1 for all molecular
subtypes. A similar hormonal treatment benefit was seen for
patients with high DCN staining in malignant cells, albeit with a
less dramatic improvement (HR: 1.17 vs. 1.35 for no hormone
treatment group) and can be at least partially explained by
molecular subtype bias since high DCN staining in malignant cells
had prognostic value for OS only for Luminal B type of tumours
(i.e. ER-positive/HER2 -positive).
Figure 5. Overall survival curves for high and low DE staining based on tumour molecular subtype. Univariate Cox regression used to
determine HR; logrank p-values reported. Molecular subtypes were defined by IHC expression of ER, HER2 and Ki-67 as suggested by Cheang et al.
(2009) and Hugh et al. (2009). DE: Decorin staining in malignant epithelial tissue. HR: Hazard ratio.
doi:10.1371/journal.pone.0030992.g005
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quantitative SRM-MS in fresh frozen tissue, as well as
preliminary validation of two markers using another analytical
technology (i.e. IHC), a different sample preparation (FFPE), and
two independent sample populations. Of the proteins showing
significant differential expression between LN positive and LN
negative samples based on SRM-MS, 10 had commercially
available antibodies suitable for use on FFPE tissue. Despite the
different technique and sample type, 5 of the 10 antibodies
showed statistically significant correlation with LN status when
protein expression was analyzed by IHC in an independent
cohort of 39 patients (UHN). When the analysis was extended to
234 cases (UHN), DCN and HSP90B1 remained statically
significant. Moreover, when prognostic TMAs (NCI) were used
a significant association with decreased survival was observed.
Although the verification of DCN and HSP90B1 in an in-
dependent cohort was encouraging, the other proteins identified
during discovery for which commercial antibodies were available
did not replicate in this assay. There are several factors that may
have contributed to the differences in protein identification seen
in different stages of this study. SRM-MS and IHC measure
protein expression in entirely orthogonal ways, (i.e. SRM-MS
detects peptides as surrogates of protein expression, while IHC
detects specific epitopes of target proteins) and formalin fixation
may alter protein quality (e.g. through crosslinking). Furthermore,
different cohorts were used and therefore inherent differences
between the two cohorts and heterogeneity of the samples are to
be expected.
This study aims to present the proteomics’ discovery results
and their correlation with IHC focusing on their prognostic
capability. We found it promising that using an inexpensive and
ubiquitous technique such as IHC, we were able to corroborate
that both groups (LN positive vs LN negative breast cancers)
have significant differences in respect to these two proteins, and
that these differences are associated with decreased overall
survival. External validation of these markers using blotting or
molecular techniques and separate cohorts would be the next
desirable step.
As with any IHC-based study, limitations exist due to limited
technical reproducibility and subjective interpretation of IHC
staining. In addition, the strong ubiquitous DCN stroma staining
makes it difficult to evaluate DCN epithelial staining in some
invasive cancers with a single-cell invasive pattern. As well, the
generally positive HSP90B1 epithelial expression forces the
Figure 6. Overall survival curves for high and low HE staining based on tumour molecular subtype. Univariate Cox regression used to
determine HR; logrank p-values reported. Molecular subtypes were defined by IHC expression of ER, HER2 and Ki-67 as suggested by Cheang et al.
(2009) and Hugh et al. (2009). HE: HSP90B1 staining in malignant epithelial tissue. HR: Hazard ratio.
doi:10.1371/journal.pone.0030992.g006
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one with higher expression than the other.
Using proteomic profiling of primary breast cancers two new
promising prognostic and predictive markers were found to
discriminate patients with worse survival. In addition, high
expression of HSP90B1 appears to be a marker for distant meta-
stasis and a predictive marker for hormone therapy benefit even
in patients with negative hormone receptor status. Additional
research is needed to determine the clinical role for these
markers.
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